Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes o…
Drug Manufacturers - Specialty & Generic
US, EmeryVille [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -65.52 | -120.42 | 349.27 | |
| Graham Fair Price | 525.26 | 2.68 | 0.43 | |
| PEG | -99.94 | 0.01 | -20.97 | |
| Price/Book | -8.92 | 2.65 | 2.91 | |
| Price/Cash Flow | -37.42 | -93.98 | 150.19 | |
| Prices/Earnings | -97.73 | -46.95 | 2064.78 | |
| Price/Sales | -0.88 | 32.25 | 32.53 | |
| Price/FCF | -37.42 | -93.98 | 150.19 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -7.07 | 0.78 | 0.84 | |
| Operating Margin | -113.74 | -0.33 | -0.15 | |
| ROA | 3924.70 | < 0.005 | < 0.005 | |
| ROE | < 0.005 | -0.01 | 3905.32 | |
| ROIC | < 0.005 | -0.01 | -599.88 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.02 | -79.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -2.66 | -0.95 | 64.18 | |
| EPS QOQ | -0.98 | -40.41 | -4004.61 | |
| FCF QOQ | -0.61 | -2.45 | -301.99 | |
| Revenue QOQ | -0.20 | -0.09 | 56.82 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 551.97 | 507.25 | -8.10 | |
| Days Sales Outstanding (DSO) | 72.09 | 81.78 | 13.45 | |
| Inventory Turnover | 0.16 | 0.18 | 8.82 | |
| Debt/Capitalization | 0.29 | 0.27 | -7.98 | |
| Quick Ratio | 12.65 | 13.74 | 8.64 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.81 | 4.75 | -1.20 | |
| Cash | 5.74 | 5.56 | -3.14 | |
| Capex | -0.01 | < 0.005 | 56.80 | |
| Free Cash Flow | 0.09 | -0.13 | 43.80 | |
| Revenue | 0.43 | 0.39 | -9.22 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad